Next Article in Journal
Nuclear Trafficking of Retroviral RNAs and Gag Proteins during Late Steps of Replication
Next Article in Special Issue
Development of Hematopoietic Stem Cell Based Gene Therapy for HIV-1 Infection: Considerations for Proof of Concept Studies and Translation to Standard Medical Practice
Previous Article in Journal
Genome Scale Transcriptomics of Baculovirus-Insect Interactions
Previous Article in Special Issue
Foamy Virus Vectors for HIV Gene Therapy
Article Menu

Export Article

Open AccessReview
Viruses 2013, 5(11), 2748-2766;

Newer Gene Editing Technologies toward HIV Gene Therapy

Center of Excellence in Infectious Disease, Department of Biomedical Sciences, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA
Authors to whom correspondence should be addressed.
Received: 17 September 2013 / Revised: 2 November 2013 / Accepted: 8 November 2013 / Published: 14 November 2013
(This article belongs to the Special Issue Gene Therapy for Retroviral Infections)
Full-Text   |   PDF [559 KB, uploaded 12 May 2015]   |  


Despite the great success of highly active antiretroviral therapy (HAART) in ameliorating the course of HIV infection, alternative therapeutic approaches are being pursued because of practical problems associated with life-long therapy. The eradication of HIV in the so-called “Berlin patient” who received a bone marrow transplant from a CCR5-negative donor has rekindled interest in genome engineering strategies to achieve the same effect. Precise gene editing within the cells is now a realistic possibility with recent advances in understanding the DNA repair mechanisms, DNA interaction with transcription factors and bacterial defense mechanisms. Within the past few years, four novel technologies have emerged that can be engineered for recognition of specific DNA target sequences to enable site-specific gene editing: Homing Endonuclease, ZFN, TALEN, and CRISPR/Cas9 system. The most recent CRISPR/Cas9 system uses a short stretch of complementary RNA bound to Cas9 nuclease to recognize and cleave target DNA, as opposed to the previous technologies that use DNA binding motifs of either zinc finger proteins or transcription activator-like effector molecules fused to an endonuclease to mediate sequence-specific DNA cleavage. Unlike RNA interference, which requires the continued presence of effector moieties to maintain gene silencing, the newer technologies allow permanent disruption of the targeted gene after a single treatment. Here, we review the applications, limitations and future prospects of novel gene-editing strategies for use as HIV therapy. View Full-Text
Keywords: zinc finger nuclease; transcription activator-like effector nuclease; CRISPR/Cas 9; gene editing; HIV-1 therapy; CCR5 disruption zinc finger nuclease; transcription activator-like effector nuclease; CRISPR/Cas 9; gene editing; HIV-1 therapy; CCR5 disruption

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Manjunath, N.; Yi, G.; Dang, Y.; Shankar, P. Newer Gene Editing Technologies toward HIV Gene Therapy. Viruses 2013, 5, 2748-2766.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top